WO2000042996A3 - Use of anticonvulsant derivatives for treating cluster headaches - Google Patents

Use of anticonvulsant derivatives for treating cluster headaches Download PDF

Info

Publication number
WO2000042996A3
WO2000042996A3 PCT/US2000/000919 US0000919W WO0042996A3 WO 2000042996 A3 WO2000042996 A3 WO 2000042996A3 US 0000919 W US0000919 W US 0000919W WO 0042996 A3 WO0042996 A3 WO 0042996A3
Authority
WO
WIPO (PCT)
Prior art keywords
cluster headaches
alkyl
anticonvulsant derivatives
treating cluster
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/000919
Other languages
French (fr)
Other versions
WO2000042996A2 (en
Inventor
Enrique Carrazana
Steve D Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU27268/00A priority Critical patent/AU771388B2/en
Priority to IL14440600A priority patent/IL144406A0/en
Priority to MXPA01007350A priority patent/MXPA01007350A/en
Priority to JP2000594453A priority patent/JP2002535270A/en
Priority to AT00905615T priority patent/ATE279921T1/en
Priority to EP00905615A priority patent/EP1143967B1/en
Priority to BR0008176-0A priority patent/BR0008176A/en
Priority to DE60015070T priority patent/DE60015070T2/en
Priority to NZ513115A priority patent/NZ513115A/en
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Priority to DK00905615T priority patent/DK1143967T3/en
Priority to HU0105154A priority patent/HUP0105154A3/en
Priority to CA002359541A priority patent/CA2359541C/en
Publication of WO2000042996A2 publication Critical patent/WO2000042996A2/en
Publication of WO2000042996A3 publication Critical patent/WO2000042996A3/en
Priority to NO20013554A priority patent/NO20013554D0/en
Priority to IL144406A priority patent/IL144406A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

The use of anticonvulsant derivatives of formula (I) treating cluster headaches is disclosed. Wherein X is CH2 or oxygen; R1 is hydrogen of C1-C4 alkyl; and R2, R3, R4 and R5 are independently hydrogen or C1-C3 alkyl and, when X is CH2, R4 and R5 may be alkene groups joined to form a benzene ring and, when X is oxygen, R2 and R3 and/or R4 and R5 together may be a methylenedioxy group of the following formula (II): wherein R6 and R7 are the same or different and are hydrogen, C1-C¿3 alkyl or R6 and R7 together with the carbon to which they are attached are joined to form a cyclopentyl or cyclohexyl ring.
PCT/US2000/000919 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches Ceased WO2000042996A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NZ513115A NZ513115A (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives useful in treating cluster headaches
MXPA01007350A MXPA01007350A (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives useful in treating cluster headaches.
DK00905615T DK1143967T3 (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives suitable for the treatment of Horton's headache
AT00905615T ATE279921T1 (en) 1999-01-19 2000-01-13 USE OF ANTICONVULSIVE DERIVATIVES TO TREAT CLUSTER HEADACHE
EP00905615A EP1143967B1 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches
BR0008176-0A BR0008176A (en) 1999-01-19 2000-01-13 Anti-seizure derivatives useful in the treatment of cluster headaches
DE60015070T DE60015070T2 (en) 1999-01-19 2000-01-13 USE OF ANTICONVULSIVE DERIVATIVES FOR THE TREATMENT OF THE CLUSTER HEADACHE
AU27268/00A AU771388B2 (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives useful in treating cluster headaches
JP2000594453A JP2002535270A (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives useful in the treatment of cluster headache
IL14440600A IL144406A0 (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives useful in treating cluster headaches
HU0105154A HUP0105154A3 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches
CA002359541A CA2359541C (en) 1999-01-19 2000-01-13 Anticonvulsant derivatives useful in treating cluster headaches
NO20013554A NO20013554D0 (en) 1999-01-19 2001-07-18 Anticonvulsant derivatives that can be used in the treatment of cluster headaches
IL144406A IL144406A (en) 1999-01-19 2001-07-18 Anticonvulsant derivatives useful in treating cluster headaches

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638899P 1999-01-19 1999-01-19
US60/116,388 1999-01-19

Publications (2)

Publication Number Publication Date
WO2000042996A2 WO2000042996A2 (en) 2000-07-27
WO2000042996A3 true WO2000042996A3 (en) 2000-12-07

Family

ID=22366884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000919 Ceased WO2000042996A2 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Country Status (24)

Country Link
US (1) US6319903B1 (en)
EP (1) EP1143967B1 (en)
JP (1) JP2002535270A (en)
KR (1) KR100653326B1 (en)
CN (1) CN1182845C (en)
AT (1) ATE279921T1 (en)
AU (1) AU771388B2 (en)
BR (1) BR0008176A (en)
CA (1) CA2359541C (en)
CZ (1) CZ20012620A3 (en)
DE (1) DE60015070T2 (en)
DK (1) DK1143967T3 (en)
ES (1) ES2228465T3 (en)
HU (1) HUP0105154A3 (en)
IL (2) IL144406A0 (en)
MX (1) MXPA01007350A (en)
MY (1) MY121486A (en)
NO (1) NO20013554D0 (en)
NZ (1) NZ513115A (en)
PT (1) PT1143967E (en)
TR (1) TR200102711T2 (en)
TW (1) TWI248360B (en)
WO (1) WO2000042996A2 (en)
ZA (1) ZA200106786B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
IL154470A0 (en) * 2000-08-17 2003-09-17 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
WO2003072138A1 (en) * 2002-02-26 2003-09-04 Ortho-Mcneil Pharmaceutical Inc. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2003225813A1 (en) * 2002-03-18 2003-10-08 Roger K. Cady Preemptive prophylaxis of migraine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (en) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS
ES2310366T3 (en) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv NEW DERIVATIVES OF HETEROARIL SULFONAMIDE BENZO-CONDENSED USEFUL AS ANTI-CONVERSIVE AGENTS.
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
JP2008545650A (en) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Method for producing sulfamide derivative
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2555066T3 (en) 2006-11-17 2015-12-28 Supernus Pharmaceuticals, Inc. Topiramate sustained release formulations
ES2645719T3 (en) 2006-12-04 2017-12-07 Supernus Pharmaceuticals, Inc. Enhanced immediate release topiramate formulations
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN102579367B (en) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition
WO2013139292A1 (en) 2012-03-23 2013-09-26 中国人民解放军军事医学科学院毒物药物研究所 Joint product containing synephrine and topiramate
CN103316026B (en) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 Contain joint product of Phentermine and Topiramate and preparation method thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US20240131116A1 (en) * 2021-02-24 2024-04-25 Nbo Pharma Llc Methods and threapeutic combinations for treating idiopathic intracranial hypertension and cluster headaches

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
WO1997013510A1 (en) * 1995-10-13 1997-04-17 New England Medical Center Hospitals, Inc. Treatment of migraine
WO1998015270A1 (en) * 1996-10-08 1998-04-16 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
WO1997013510A1 (en) * 1995-10-13 1997-04-17 New England Medical Center Hospitals, Inc. Treatment of migraine
WO1998015270A1 (en) * 1996-10-08 1998-04-16 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"The Merck Manual", 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J., XP002144176 *
HERING R ET AL: "Sodium valproate in the treatment of cluster headache: an open clinical trial.", CEPHALALGIA, (1989 SEP) 9 (3) 195-8., XP000923459 *
KUZNIECKY R ET AL: "Topiramate increases cerebral GABA in healthy humans.", NEUROLOGY, (1998 AUG) 51 (2) 627-9., XP000923467 *
WHEELER S.D.: "Significance of migrainous features in cluster headache: Divalproex responsiveness.", HEADACHE, (1998) 38/7 (547-551)., XP000923465 *
WHEELER, STEVE D. (1) ET AL: "Topiramate -treated cluster headache.", NEUROLOGY, (JULY 13, 1999) VOL. 53, NO. 1, PP. 234-236., XP000921301 *

Also Published As

Publication number Publication date
NZ513115A (en) 2004-11-26
DK1143967T3 (en) 2005-01-10
KR20010101595A (en) 2001-11-14
ATE279921T1 (en) 2004-11-15
DE60015070T2 (en) 2006-01-05
CN1182845C (en) 2005-01-05
HUP0105154A2 (en) 2002-04-29
EP1143967B1 (en) 2004-10-20
CA2359541C (en) 2005-06-21
KR100653326B1 (en) 2006-12-04
CZ20012620A3 (en) 2002-09-11
CA2359541A1 (en) 2000-07-27
US6319903B1 (en) 2001-11-20
DE60015070D1 (en) 2004-11-25
EP1143967A2 (en) 2001-10-17
AU771388B2 (en) 2004-03-18
MXPA01007350A (en) 2003-06-06
MY121486A (en) 2006-01-28
HUP0105154A3 (en) 2004-10-28
ES2228465T3 (en) 2005-04-16
IL144406A0 (en) 2002-05-23
JP2002535270A (en) 2002-10-22
WO2000042996A2 (en) 2000-07-27
PT1143967E (en) 2005-01-31
NO20013554L (en) 2001-07-18
TWI248360B (en) 2006-02-01
IL144406A (en) 2006-08-20
CN1352555A (en) 2002-06-05
ZA200106786B (en) 2002-11-18
NO20013554D0 (en) 2001-07-18
AU2726800A (en) 2000-08-07
BR0008176A (en) 2001-11-06
TR200102711T2 (en) 2001-12-21

Similar Documents

Publication Publication Date Title
WO2000042996A3 (en) Use of anticonvulsant derivatives for treating cluster headaches
WO2000061138A8 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
WO2002003984A3 (en) Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
WO2000061139A8 (en) Anticonvulsant derivatives useful in reducing blood glucose levels
CA2369093A1 (en) Anticonvulsant derivatives useful in lowering lipids
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
GB0007405D0 (en) Compounds
CA2369091A1 (en) Anticonvulsant derivatives useful in lowering blood pressure
TW376409B (en) Stabilizer mixture
TW326446B (en) 4-Acylaminopiperidin-N-oxyle, process for preparation thereof and use of the same
TW334423B (en) Tricyclic 1-aminoethylpyrrole-derivatives
IL110091A (en) POLYSUBSTITUTED IMIDAZO £4, 5-c| PYRIDIN-4-AMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TW328089B (en) New azolidinediones as antihyperglycemic agents
WO2000042995A3 (en) Use of anticonvulsant derivatives for treating transformed migraine
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
WO2003035620A1 (en) Bicyclic compound
NZ314570A (en) Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
NZ334981A (en) Anti-convulsant derivatives such as topiramate for treating neuropathic pain
TW355124B (en) Substituted pyrazolylpyrazole derivatives and their use as herbicides
UA41880C2 (en) Serotoninergic derivatives of ergolin and a pharmaceutical composition
CA2244417A1 (en) Optically active bisoxazoline compounds, production and use thereof
CA2247946A1 (en) Anticachectic composition
WO2000048549A3 (en) Anticonvulsant derivatives useful in treating essential tremor
WO2000023059A3 (en) Use of anticonvulsant derivatives for treating alcohol dependency
WO2000066108A3 (en) Anticonvulsant derivatives useful in treating cocaine dependency

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00802901.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PV2001-2620

Country of ref document: CZ

Ref document number: 144406

Country of ref document: IL

Ref document number: 27268/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2359541

Country of ref document: CA

Ref document number: 2359541

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 594453

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007350

Country of ref document: MX

Ref document number: 1020017009077

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 513115

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000905615

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/06786

Country of ref document: ZA

Ref document number: 200106786

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001/02711

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 2000905615

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017009077

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2620

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-2620

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 27268/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000905615

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017009077

Country of ref document: KR